{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T06:12:46Z","timestamp":1789711966173,"version":"4.0.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,9,21]],"date-time":"2010-09-21T00:00:00Z","timestamp":1285027200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1007\/s00262-010-0916-z","type":"journal-article","created":{"date-parts":[[2010,9,20]],"date-time":"2010-09-20T02:34:53Z","timestamp":1284950093000},"page":"23-35","source":"Crossref","is-referenced-by-count":28,"title":["MAGE-A3 and MAGE-A4 specific CD4+ T cells in head and neck cancer patients: detection of naturally acquired responses and identification of new epitopes"],"prefix":"10.1007","volume":"60","author":[{"given":"Val\u00e9rie","family":"Cesson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Paul","family":"Rivals","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anette","family":"Escher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Piotet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kris","family":"Thielemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vilmos","family":"Posevitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danijel","family":"Dojcinovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Monnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Speiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Bron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,9,21]]},"reference":[{"key":"916_CR1","first-page":"151","volume":"62","author":"TK Hoffmann","year":"2005","unstructured":"Hoffmann TK, Bier H, Donnenberg AD, Whiteside TL, De Leo AB (2005) p53 as an immunotherapeutic target in head and neck cancer. Adv Otorhinolaryngol 62:151\u2013160. doi: 10.1159\/000082505","journal-title":"Adv Otorhinolaryngol"},{"issue":"4","key":"916_CR2","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1084\/jem.191.4.625","volume":"191","author":"E Jager","year":"2000","unstructured":"Jager E, Jager D, Karbach J, Chen YT, Ritter G, Nagata Y, Gnjatic S, Stockert E, Arand M, Old LJ, Knuth A (2000) Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101\u20130103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma. J Exp Med 191(4):625\u2013630","journal-title":"J Exp Med"},{"issue":"15","key":"916_CR3","doi-asserted-by":"crossref","first-page":"8862","DOI":"10.1073\/pnas.1133324100","volume":"100","author":"S Gnjatic","year":"2003","unstructured":"Gnjatic S, Atanackovic D, Jager E, Matsuo M, Selvakumar A, Altorki NK, Maki RG, Dupont B, Ritter G, Chen YT, Knuth A, Old LJ (2003) Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. Proc Natl Acad Sci USA 100(15):8862\u20138867. doi: 10.1073\/pnas.1133324100","journal-title":"Proc Natl Acad Sci USA"},{"issue":"13","key":"916_CR4","first-page":"5161","volume":"61","author":"DG McNeel","year":"2001","unstructured":"McNeel DG, Nguyen LD, Disis ML (2001) Identification of T helper epitopes from prostatic acid phosphatase. Cancer Res 61(13):5161\u20135167","journal-title":"Cancer Res"},{"issue":"10","key":"916_CR5","doi-asserted-by":"crossref","first-page":"6769","DOI":"10.4049\/jimmunol.177.10.6769","volume":"177","author":"G Bioley","year":"2006","unstructured":"Bioley G, Jandus C, Tuyaerts S, Rimoldi D, Kwok WW, Speiser DE, Tiercy JM, Thielemans K, Cerottini JC, Romero P (2006) Melan-a\/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers. J Immunol 177(10):6769\u20136779","journal-title":"J Immunol"},{"issue":"2","key":"916_CR6","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/ijc.22309","volume":"120","author":"C Groeper","year":"2007","unstructured":"Groeper C, Gambazzi F, Zajac P, Bubendorf L, Adamina M, Rosenthal R, Zerkowski HR, Heberer M, Spagnoli GC (2007) Cancer\/testis antigen expression and specific cytotoxic T lymphocyte responses in nonsmall cell lung cancer. Int J Cancer 120(2):337\u2013343","journal-title":"Int J Cancer"},{"issue":"3","key":"916_CR7","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/ijc.2910630313","volume":"63","author":"F Brasseur","year":"1995","unstructured":"Brasseur F, Rimoldi D, Lienard D, Lethe B, Carrel S, Arienti F, Suter L, Vanwijck R, Bourlond A, Humblet Y et al (1995) Expression of mage genes in primary and metastatic cutaneous melanoma. Int J Cancer 63(3):375\u2013380","journal-title":"Int J Cancer"},{"key":"916_CR100","doi-asserted-by":"crossref","unstructured":"Cuffel C, Rivals JP, Zaugg Y, Salvi S, Seelentag W, Speiser DE, Li\u00e9nard D, Monnier P, Romero P, Bron L, Rimoldi D (2010) Pattern and clinical significance of cancer-testis gene expression in head and neck squamous cell carcinoma. Int J Cancer [Epub ahead of print]","DOI":"10.1002\/ijc.25607"},{"key":"916_CR8","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.smim.2010.03.004","volume":"22","author":"DE Speiser","year":"2010","unstructured":"Speiser DE, Romero P (2010) Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity. Semin Immunol 22:144\u2013154. doi: 10.1016\/j.smim.2010.03.004","journal-title":"Semin Immunol"},{"issue":"5","key":"916_CR9","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.4049\/jimmunol.172.5.3289","volume":"172","author":"D Atanackovic","year":"2004","unstructured":"Atanackovic D, Altorki NK, Stockert E, Williamson B, Jungbluth AA, Ritter E, Santiago D, Ferrara CA, Matsuo M, Selvakumar A, Dupont B, Chen YT, Hoffman EW, Ritter G, Old LJ, Gnjatic S (2004) Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients. J Immunol 172(5):3289\u20133296","journal-title":"J Immunol"},{"issue":"8","key":"916_CR10","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1084\/jem.187.8.1349","volume":"187","author":"E Stockert","year":"1998","unstructured":"Stockert E, Jager E, Chen YT, Scanlan MJ, Gout I, Karbach J, Arand M, Knuth A, Old LJ (1998) A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 187(8):1349\u20131354","journal-title":"J Exp Med"},{"issue":"2","key":"916_CR11","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s00262-005-0063-0","volume":"55","author":"T Hanagiri","year":"2006","unstructured":"Hanagiri T, van Baren N, Neyns B, Boon T, Coulie PG (2006) Analysis of a rare melanoma patient with a spontaneous CTL response to a MAGE-A3 peptide presented by HLA-A1. Cancer Immunol Immunother 55(2):178\u2013184","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"916_CR12","first-page":"221","volume":"3","author":"C Scheibenbogen","year":"1997","unstructured":"Scheibenbogen C, Lee KH, Mayer S, Stevanovic S, Moebius U, Herr W, Rammensee HG, Keilholz U (1997) A sensitive elispot assay for detection of CD8+ T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza proteins in the blood of healthy donors and melanoma patients. Clin Cancer Res 3(2):221\u2013226","journal-title":"Clin Cancer Res"},{"issue":"12","key":"916_CR13","first-page":"4831","volume":"6","author":"MV Dhodapkar","year":"2000","unstructured":"Dhodapkar MV, Young JW, Chapman PB, Cox WI, Fonteneau JF, Amigorena S, Houghton AN, Steinman RM, Bhardwaj N (2000) Paucity of functional T-cell memory to melanoma antigens in healthy donors and melanoma patients. Clin Cancer Res 6(12):4831\u20134838","journal-title":"Clin Cancer Res"},{"issue":"4","key":"916_CR14","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.4049\/jimmunol.179.4.2627","volume":"179","author":"M Inokuma","year":"2007","unstructured":"Inokuma M, dela Rosa C, Schmitt C, Haaland P, Siebert J, Petry D, Tang M, Suni MA, Ghanekar SA, Gladding D, Dunne JF, Maino VC, Disis ML, Maecker HT (2007) Functional T cell responses to tumor antigens in breast cancer patients have a distinct phenotype and cytokine signature. J Immunol 179(4):2627\u20132633","journal-title":"J Immunol"},{"issue":"2","key":"916_CR15","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/00002371-200403000-00006","volume":"27","author":"V Vantomme","year":"2004","unstructured":"Vantomme V, Dantinne C, Amrani N, Permanne P, Gheysen D, Bruck C, Stoter G, Britten CM, Keilholz U, Lamers CH, Marchand M, Delire M, Gueguen M (2004) Immunologic analysis of a phase I\/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumors. J Immunother 27(2):124\u2013135","journal-title":"J Immunother"},{"issue":"5","key":"916_CR16","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1084\/jem.189.5.767","volume":"189","author":"P Chaux","year":"1999","unstructured":"Chaux P, Vantomme V, Stroobant V, Thielemans K, Corthals J, Luiten R, Eggermont AM, Boon T, van der Bruggen P (1999) Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. J Exp Med 189(5):767\u2013778","journal-title":"J Exp Med"},{"key":"916_CR17","first-page":"7","volume":"9","author":"P Guillaume","year":"2009","unstructured":"Guillaume P, Dojcinovic D, Luescher IF (2009) Soluble MHC\u2013peptide complexes: tools for the monitoring of T cell responses in clinical trials and basic research. Cancer Immun 9:7","journal-title":"Cancer Immun"},{"issue":"3","key":"916_CR18","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1182\/blood-2005-02-0607","volume":"106","author":"H Nishikawa","year":"2005","unstructured":"Nishikawa H, Jager E, Ritter G, Old LJ, Gnjatic S (2005) CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients. Blood 106(3):1008\u20131011. doi: 10.1182\/blood-2005-02-0607","journal-title":"Blood"},{"issue":"3","key":"916_CR19","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1182\/blood-2002-03-0933","volume":"101","author":"G Consogno","year":"2003","unstructured":"Consogno G, Manici S, Facchinetti V, Bachi A, Hammer J, Conti-Fine BM, Rugarli C, Traversari C, Protti MP (2003) Identification of immunodominant regions among promiscuous HLA-DR-restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3. Blood 101(3):1038\u20131044. doi: 10.1182\/blood-2002-03-0933","journal-title":"Blood"},{"issue":"5","key":"916_CR20","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1084\/jem.189.5.871","volume":"189","author":"S Manici","year":"1999","unstructured":"Manici S, Sturniolo T, Imro MA, Hammer J, Sinigaglia F, Noppen C, Spagnoli G, Mazzi B, Bellone M, Dellabona P, Protti MP (1999) Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. J Exp Med 189(5):871\u2013876","journal-title":"J Exp Med"},{"issue":"2","key":"916_CR21","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00262-007-0364-6","volume":"57","author":"J Marturano","year":"2008","unstructured":"Marturano J, Longhi R, Casorati G, Protti MP (2008) MAGE-A3(161\u2013175) contains an HLA-DRBETA4 restricted natural epitope poorly formed through indirect presentation by dendritic cells. Cancer Immunol Immunother 57(2):207\u2013215. doi: 10.1007\/s00262-007-0364-6","journal-title":"Cancer Immunol Immunother"},{"issue":"27","key":"916_CR22","doi-asserted-by":"crossref","first-page":"11241","DOI":"10.1073\/pnas.0902015106","volume":"106","author":"HH Chu","year":"2009","unstructured":"Chu HH, Moon JJ, Takada K, Pepper M, Molitor JA, Schacker TW, Hogquist KA, Jameson SC, Jenkins MK (2009) Positive selection optimizes the number and function of MHCII-restricted CD4+ T cell clones in the naive polyclonal repertoire. Proc Natl Acad Sci USA 106(27):11241\u201311245. doi: 10.1073\/pnas.0902015106","journal-title":"Proc Natl Acad Sci USA"},{"issue":"15","key":"916_CR23","doi-asserted-by":"crossref","first-page":"5581","DOI":"10.1158\/1078-0432.CCR-04-2585","volume":"11","author":"Y Miyahara","year":"2005","unstructured":"Miyahara Y, Naota H, Wang L, Hiasa A, Goto M, Watanabe M, Kitano S, Okumura S, Takemitsu T, Yuta A, Majima Y, Lemonnier FA, Boon T, Shiku H (2005) Determination of cellularly processed HLA-A2402-restricted novel CTL epitopes derived from two cancer germ line genes, MAGE-A4 and sage. Clin Cancer Res 11(15):5581\u20135589. doi: 10.1158\/1078-0432.CCR-04-2585","journal-title":"Clin Cancer Res"},{"issue":"1","key":"916_CR24","doi-asserted-by":"crossref","first-page":"575","DOI":"10.4049\/jimmunol.169.1.575","volume":"169","author":"S Graff-Dubois","year":"2002","unstructured":"Graff-Dubois S, Faure O, Gross DA, Alves P, Scardino A, Chouaib S, Lemonnier FA, Kosmatopoulos K (2002) Generation of CTL recognizing an HLA-A*0201-restricted epitope shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 tumor antigens: implication in a broad-spectrum tumor immunotherapy. J Immunol 169(1):575\u2013580","journal-title":"J Immunol"},{"issue":"10","key":"916_CR25","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1002\/(SICI)1521-4141(199910)29:10<3329::AID-IMMU3329>3.0.CO;2-7","volume":"29","author":"MT Duffour","year":"1999","unstructured":"Duffour MT, Chaux P, Lurquin C, Cornelis G, Boon T, van der Bruggen P (1999) A MAGE-A4 peptide presented by HLA-A2 is recognized by cytolytic T lymphocytes. Eur J Immunol 29(10):3329\u20133337. doi: 10.1002\/(SICI)1521-4141(199910)29:10<3329:AID-IMMU3329>3.0.CO;2-7","journal-title":"Eur J Immunol"},{"issue":"7","key":"916_CR26","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/sj.bjc.6604966","volume":"100","author":"T Ohkuri","year":"2009","unstructured":"Ohkuri T, Wakita D, Chamoto K, Togashi Y, Kitamura H, Nishimura T (2009) Identification of novel helper epitopes of MAGE-A4 tumour antigen: useful tool for the propagation of Th1 cells. Br J Cancer 100(7):1135\u20131143. doi: 10.1038\/sj.bjc.6604966","journal-title":"Br J Cancer"},{"issue":"1","key":"916_CR27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0198-8859(97)00255-3","volume":"59","author":"I Kawashima","year":"1998","unstructured":"Kawashima I, Hudson SJ, Tsai V, Southwood S, Takesako K, Appella E, Sette A, Celis E (1998) The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum Immunol 59(1):1\u201314","journal-title":"Hum Immunol"},{"key":"916_CR28","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1034\/j.1600-065X.2002.18806.x","volume":"188","author":"P Bruggen Van Der","year":"2002","unstructured":"Van Der Bruggen P, Zhang Y, Chaux P, Stroobant V, Panichelli C, Schultz ES, Chapiro J, Van Den Eynde BJ, Brasseur F, Boon T (2002) Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev 188:51\u201364","journal-title":"Immunol Rev"},{"issue":"12","key":"916_CR29","first-page":"4773","volume":"61","author":"H Kobayashi","year":"2001","unstructured":"Kobayashi H, Song Y, Hoon DS, Appella E, Celis E (2001) Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles. Cancer Res 61(12):4773\u20134778","journal-title":"Cancer Res"},{"issue":"6","key":"916_CR30","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/(SICI)1097-0215(19970611)71:6<932::AID-IJC3>3.0.CO;2-Z","volume":"71","author":"C Scheibenbogen","year":"1997","unstructured":"Scheibenbogen C, Lee KH, Stevanovic S, Witzens M, Willhauck M, Waldmann V, Naeher H, Rammensee HG, Keilholz U (1997) Analysis of the T cell response to tumor and viral peptide antigens by an IFNgamma-ELISPOT assay. Int J Cancer 71(6):932\u2013936. doi: 10.1002\/(SICI)1097-0215(19970611)71:6<932:AID-IJC3>3.0.CO;2-Z","journal-title":"Int J Cancer"},{"issue":"12","key":"916_CR31","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1007\/s00262-007-0338-8","volume":"56","author":"HG Zhang","year":"2007","unstructured":"Zhang HG, Chen HS, Peng JR, Shang XY, Zhang J, Xing Q, Pang XW, Qin LL, Fei R, Mei MH, Leng XS, Chen WF (2007) Specific CD8(+)T cell responses to HLA-A2 restricted MAGE-A3 p271\u2013279 peptide in hepatocellular carcinoma patients without vaccination. Cancer Immunol Immunother 56(12):1945\u20131954. doi: 10.1007\/s00262-007-0338-8","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"916_CR32","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/hed.20739","volume":"30","author":"O Alhamarneh","year":"2008","unstructured":"Alhamarneh O, Amarnath SM, Stafford ND, Greenman J (2008) Regulatory T cells: what role do they play in antitumor immunity in patients with head and neck cancer? Head Neck 30(2):251\u2013261. doi: 10.1002\/hed.20739","journal-title":"Head Neck"},{"issue":"1","key":"916_CR33","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1001\/archotol.125.1.82","volume":"125","author":"S Lang","year":"1999","unstructured":"Lang S, Whiteside TL, Lebeau A, Zeidler R, Mack B, Wollenberg B (1999) Impairment of T-cell activation in head and neck cancer in situ and in vitro: strategies for an immune restoration. Arch Otolaryngol Head Neck Surg 125(1):82\u201388","journal-title":"Arch Otolaryngol Head Neck Surg"},{"issue":"5","key":"916_CR34","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/hed.20331","volume":"28","author":"MR Young","year":"2006","unstructured":"Young MR (2006) Protective mechanisms of head and neck squamous cell carcinomas from immune assault. Head Neck 28(5):462\u2013470. doi: 10.1002\/hed.20331","journal-title":"Head Neck"},{"issue":"5","key":"916_CR35","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1073\/pnas.0707140104","volume":"105","author":"D Atanackovic","year":"2008","unstructured":"Atanackovic D, Altorki NK, Cao Y, Ritter E, Ferrara CA, Ritter G, Hoffman EW, Bokemeyer C, Old LJ, Gnjatic S (2008) Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proc Natl Acad Sci USA 105(5):1650\u20131655. doi: 10.1073\/pnas.0707140104","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"916_CR36","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S0959-8049(02)00479-3","volume":"39","author":"M Marchand","year":"2003","unstructured":"Marchand M, Punt CJ, Aamdal S, Escudier B, Kruit WH, Keilholz U, Hakansson L, van Baren N, Humblet Y, Mulders P, Avril MF, Eggermont AM, Scheibenbogen C, Uiters J, Wanders J, Delire M, Boon T, Stoter G (2003) Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur J Cancer 39(1):70\u201377","journal-title":"Eur J Cancer"},{"issue":"12","key":"916_CR37","doi-asserted-by":"crossref","first-page":"7253","DOI":"10.4049\/jimmunol.165.12.7253","volume":"165","author":"D Rimoldi","year":"2000","unstructured":"Rimoldi D, Rubio-Godoy V, Dutoit V, Lienard D, Salvi S, Guillaume P, Speiser D, Stockert E, Spagnoli G, Servis C, Cerottini JC, Lejeune F, Romero P, Valmori D (2000) Efficient simultaneous presentation of NY-ESO-1\/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma. J Immunol 165(12):7253\u20137261","journal-title":"J Immunol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-010-0916-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-010-0916-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-010-0916-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T18:39:37Z","timestamp":1559673577000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-010-0916-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,21]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["916"],"URL":"https:\/\/doi.org\/10.1007\/s00262-010-0916-z","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,21]]}}}